Probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM® modifies subpopulations of fecal lactobacilli and Clostridium difficile in the elderly.

2011-01-25
Age (Dordrecht, Netherlands) 34(1)
- Sampo J Lahtinen
- Sofia Forssten
- Juhani Aakko
- Linda Granlund
- Nina Rautonen
- Seppo Salminen
- Matti Viitanen
- Arthur C Ouwehand

PubMed: 21264685
DOI: 10.1007/s11357-011-9208-6

Study Design

Type: Randomized Controlled Trial (RCT)
Population: 31 elderly volunteers
Methods: randomized, controlled cross-over clinical trial, probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM vs plain cheese

Aging is associated with alterations in the intestinal microbiota and with immunosenescence. Probiotics have the potential to modify a selected part of the intestinal microbiota as well as improve immune functions and may, therefore, be particularly beneficial to elderly consumers. In this randomized, controlled cross-over clinical trial, we assessed the effects of a probiotic cheese containing Lactobacillus rhamnosus HN001 and Lactobacillus acidophilus NCFM on the intestinal microbiota and fecal immune markers of 31 elderly volunteers and compared these effects with the administration of the same cheese without probiotics. The probiotic cheese was found to increase the number of L. rhamnosus and L. acidophilus NCFM in the feces, suggesting the survival of the strains during the gastrointestinal transit. Importantly, probiotic cheese administration was associated with a trend towards lower counts of Clostridium difficile in the elderly, as compared with the run-in period with the plain cheese. The effect was statistically significant in the subpopulation of the elderly who harbored C. difficile at the start of the study. The probiotic cheese was not found to significantly alter the levels of the major microbial groups, suggesting that the microbial changes conferred by the probiotic cheese were limited to specific bacterial groups. Despite that the administration of the probiotic cheese to the study population has earlier been shown to significantly improve the innate immunity of the elders, we did not observe measurable changes in the fecal immune IgA concentrations. No increase in fecal calprotectin and β-defensin concentrations suggests that the probiotic treatment did not affect intestinal inflammatory markers. In conclusion, the administration of probiotic cheese containing L. rhamnosus HN001 and L. acidophilus NCFM, was associated with specific changes in the intestinal microbiota, mainly affecting specific subpopulations of intestinal lactobacilli and C. difficile, but did not have significant effects on the major microbial groups or the fecal immune markers.

Research Insights

Lactobacillus acidophilus NCFM→Increased Serum Immunoglobulin A (IgA) Levels
we did not observe measurable changes in the fecal immune IgA concentrations.
Effect
Neutral
Effect size
Small
Lactobacillus acidophilus NCFM→Reduced Beta-Defensin Level
No increase in fecal calprotectin and β-defensin concentrations suggests that the probiotic treatment did not affect intestinal inflammatory markers.
Effect
Neutral
Effect size
Small
Lactobacillus acidophilus NCFM→Reduced Calprotectin Level
No increase in fecal calprotectin and β-defensin concentrations suggests that the probiotic treatment did not affect intestinal inflammatory markers.
Effect
Neutral
Effect size
Small
Lactobacillus acidophilus NCFM→Reduced Clostridium difficile Count
probiotic cheese administration was associated with a trend towards lower counts of Clostridium difficile in the elderly, as compared with the run-in period with the plain cheese.
Effect
Neutral
Effect size
Small
Lactobacillus rhamnosus HN001→Increased Serum Immunoglobulin A (IgA) Levels
we did not observe measurable changes in the fecal immune IgA concentrations.
Effect
Neutral
Effect size
Small
Lactobacillus rhamnosus HN001→Reduced Beta-Defensin Level
No increase in fecal calprotectin and β-defensin concentrations suggests that the probiotic treatment did not affect intestinal inflammatory markers.
Effect
Neutral
Effect size
Small
Lactobacillus rhamnosus HN001→Reduced Calprotectin Level
No increase in fecal calprotectin and β-defensin concentrations suggests that the probiotic treatment did not affect intestinal inflammatory markers.
Effect
Neutral
Effect size
Small
Lactobacillus rhamnosus HN001→Reduced Clostridium difficile Count
probiotic cheese administration was associated with a trend towards lower counts of Clostridium difficile in the elderly, as compared with the run-in period with the plain cheese.
Effect
Neutral
Effect size
Small